Heppenheimer
Well-Known Member
The enthusiasm from the second article might stem from the fact that Novovax also contains the viral membrane protein, which thus far, hasn't shown nearly as much variance as the spike protein. What I've read about most vaccine development, though, indicates that the spike protein generates the strongest antibody response, hence this is the reason why most of the research focused on the spike as a target. The response to the membrane protein might not be enough by itself provide sufficient immunity, but it could add extra protection along with the usual spike protein antibodies.I’m not who you quoted, but this came up in a search about their vaccine. Apparently their early data must look good, even without full submission. I wonder if recent quotes from Dr Fauci regarding three shots being necessary for full protection might be precursors to this, or if he’s referring to same-brand third shots? The second article posted is from a financial analyst’s point of view, but still a reasonable take
Either way, here’s to hoping.
https://seekingalpha.com/news/37355...-fully-vaccinated-two-weeks-after-second-dose
https://www.nasdaq.com/articles/nov...-the-solution-to-emerging-variants-2021-09-01
Last edited: